Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
SAN FRANCISCO, Dec. 21, 2017 -- Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology.
Included in this article is: RXi Pharmaceuticals Corp. (NASDAQ:RXII)
In a Dec. 7 Zacks Small-Cap article, John Vandermosten explained how RXi Pharmaceuticals Corp.'s self-delivering RNA interference (sd-rxRNA) technology may be used in conjunction with adoptive cell transfer (ACT) cancer therapies to "enhance their effectiveness and durability."
These ACT processes include endogenous T-cell therapy, T-cell receptor-transduced T cells and, currently most researched, tumor infiltrating lymphocyte (TIL) therapy and chimeric antigen receptor T-cell (CAR-T) therapy. The most common disease targets for TIL therapy are melanoma and solid cancers whereas for CAR-T therapy they are leukemia, lymphoma and other blood cancers.
Vandermosten noted that "ACT is especially conducive to combination therapy with interference RNA (RNAi) as it can augment ACT's efficacy, impact expression of immune cell proteins and maintain immune cells in a stem-like state, which enhances their propagation and longevity."
Continue reading this article: 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURES:
The following company mentioned in this article is a billboard sponsor of Streetwise Reports: RXi Pharmaceuticals Corp. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
Please see the end of the article for the complete disclosures: : 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform
Contact Information: Carrie Beal Amaro- Publisher ([email protected])
